Timoprazole is a unique cytoprotective agent in the rat

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Timoprazole is a substituted benzimidazole with antisecretory properties.
• It functions by inhibiting the (H+-K+)-ATPase, a key component of gastric acid secretion.

Purpose of the Study:

• To investigate the cytoprotective and antisecretory effects of timoprazole.
• To compare the efficacy of oral versus subcutaneous administration.
• To explore the interaction between timoprazole and indomethacin regarding cytoprotection.

Main Methods:

• Oral administration of timoprazole prior to challenges with boiling water, ethanol, or 0.6 N HCl in animal models.
• Histopathological evaluation of gastric mucosa for necrosis and ulceration.
• Assessment of antisecretory activity via ED50 determination.
• Pretreatment with indomethacin to evaluate its effect on timoprazole's cytoprotection.

Main Results:

• Oral timoprazole exhibited dose-dependent cytoprotection against gastric challenges (ED50: 1-3 mg/kg).
• Antisecretory ED50 for timoprazole was approximately 12 mg/kg orally.
• Subcutaneous timoprazole was antisecretory but not cytoprotective.
• Indomethacin blocked low-dose oral timoprazole's cytoprotection, but high doses overcame this blockade.
• In vitro studies showed minimal inhibition of prostaglandin cyclooxygenase and 15-hydroxyl-dehydrogenase by timoprazole.

Conclusions:

• Timoprazole possesses significant oral cytoprotective activity in the stomach.
• Its cytoprotective mechanism differs from that of mild irritants and appears independent of significant prostaglandin synthesis inhibition.
• The route of administration is critical for observing cytoprotective effects.